Road maps to achieve glycemic control in type 2 diabetes mellitus: ACE/AACE diabetes road map task force

Endocrine Practice

Volumn 13, Issue 3, 2007, Pages 260-268

  Jellinger, Paul S ^a   Davidson, Jaime A ^a   Blonde, Lawrence ^a   Einhorn, Daniel ^a   Grunberger, George ^a   Handelsman, Yehuda ^a   Hellman, Richard ^a   Lebovitz, Harold ^a   Levy, Philip ^a   Roberts, Victor L ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN; UNCLASSIFIED DRUG;

ARTICLE; BLOOD; GLUCOSE BLOOD LEVEL; HEALTH BEHAVIOR; HUMAN; KINESIOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRACTICE GUIDELINE;

BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; EXERCISE THERAPY; HEALTH BEHAVIOR; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS;

EID: 34447535582     PISSN: 1530891X     EISSN: None     Source Type: Journal    
DOI: 10.4158/EP.13.3.260     Document Type: Review

References (98)

1. American Association of Clinical Endocrinologists Pocket Guide to Management of Type 2 Diabetes. Version 3.1, 2005. (Level 4)
2. American College of Endocrinology/American Association of Clinical Endocrinologists Diabetes Recommendations Implementation Writing Committee. ACE/AACE consensus conference on the implementation of outpatient management of diabetes mellitus: consensus conference recommendations [position statement]. Endocr Pract. 2006;12(Suppl 1):6-12. (Level 4)
3. Consensus Statement Writing Committee. American College of Endocrinology consensus statement on guidelines for glycemic control. Endocr Pract. 2002;8(Suppl 1):5-11. (Level 4)
4. Bell DS, Ovalle F. Long-term efficacy of triple oral therapy for type 2 diabetes mellitus. Endocr Pract. 2002;8:271-275. (Level 3)
5. Fonseca V, Rosenstock J, Patwardhan R, Salzman A. Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: a randomized controlled trial. JAMA. 2000;283:1695-1702. (Level 2)
6. Glyburide + metformin (Glucovance) [package insert]. Princeton, NJ: Bristol-Myers Squibb Company, 2004. (Not rated)
7. Hirschberg Y, Karara AH, Pietri AO, McLeod JF. Improved control of mealtime glucose excursions with coadministration of nateglinide and metformin. Diabetes Care. 2000;23:349-353. (Level 2)
8. Moses R, Slobodniuk R, Boyages S, et al. Effect of repaglinide addition to metformin monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care. 1999;22:119-124. (Level 1)
9. Ovalle F, Bell DS. Triple oral antidiabetic therapy in type 2 diabetes mellitus. Endocr Pract. 1998;4:146-147. (Level 3)
10. Poulsen MK, Henriksen JE, Hother-Nielsen O, Beck-Nielsen H. The combined effect of triple therapy with rosiglitazone, metformin, and insulin aspart in type 2 diabetic patients. Diabetes Care. 2003;26:3273-3279. (Level 2)
11. Rosiglitazone + glimepiride (Avandaryl) [package insert]. Research Triangle Park, NC: GlaxoSmithKline, 2005. (Not rated)
12. Rosiglitazone + metformin (Avandamet) [package insert]. Research Triangle Park, NC: GlaxoSmithKline, 2005. (Not rated)
13. Wolffenbuttel BH, Gomis R, Squatrito S, Jones NP, Patwardhan RN. Addition of low-dose rosiglitazone to sulphonylurea therapy improves glycaemic control in type 2 diabetic patients. Diabet Med. 2000;17:40-47. (Level 1)
14. Acarbose (Precose) [package insert]. West Haven, CT: Bayer Pharmaceuticals, 2004. (Not rated)
15. Fischer S, Hanefeld M, Spengler M, Boehme K, Temelkova-Kurktschiev T. European study on doseresponse relationship of acarbose as a first-line drug in noninsulin-dependent diabetes mellitus: efficacy and safety of low and high doses. Acta Diabetol. 1998;35:34-40. (Level 1)
16. Goke B, Herrmann-Rinke C. The evolving role of alphaglucosidase inhibitors. Diabetes Metab Rev. 1998;14(Suppl 1):S31-S38. (Level 4)
17. Hanefeld M, Fischer S, Schulze J, et al. Therapeutic potentials of acarbose as first-line drug in NIDDM insufficiently treated with diet alone. Diabetes Care. 1991;14:732-737. (Level 1)
18. Miglitol (Glyset) [package insert]. New York, NY: Pfizer Inc, 2004. (Not rated)
19. Santeusanio F, Ventura MM, Contandini S, Compagnucci P, Moriconni V, Zaccarini P. Efficacy and safety of two different doses of acarbose in non-insulindependent diabetic patients treated by diet alone. Diabetes Nutr Metab. 1993;6:147-154. (Level 2)
20. Willms B, Ruge D. Comparison of acarbose and metformin in patients with type 2 diabetes mellitus insufficiently controlled with diet and sulphonylureas: a randomized, placebo-controlled study. Diabet Med. 1999;16:755-761. (Level 2)
21. Aschner P, Kipnes MS, Lunceford JK, Sanchez M, Mickel C, Williams-Herman DE (Sitagliptin Study 021 Group). Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care. 2006;29:2632-2637. (Level 1)
22. Buse JB, Henry RR, Han J, Kim DD, Fineman MS, Baron AD (Exenatide-113 Clinical Study Group). Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care. 2004;27:2628-2635. (Level 1)
23. Charbonnel B, Karasik A, Liu J, Wu M, Meininger G (Sitagliptin Study 020 Group). Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone. Diabetes Care. 2006;29:2638-2643. (Level 1)
24. DeFronzo RA, Ratner RE, Han J, Kim DD, Fineman MS, Baron AD. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformintreated patients with type 2 diabetes. Diabetes Care. 2005;28:1092-1100. (Level 1)
25. Exenatide (Byetta) [package insert]. San Diego, CA: Amylin Pharmaceuticals, 2005. (Not rated)
26. Fineman M, Weyer C, Maggs DG, Strobel S, Kolterman OG. The human amylin analog, pramlintide, reduces postprandial hyperglucagonemia in patients with type 2 diabetes mellitus. Horm Metab Res. 2002;34:504-508. (Level 1)
27. Heine RJ, Van Gaal LF, Johns D, Mihm MJ, Widel MH, Brodows RG (GWAA Study Group). Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial. Ann Intern Med. 2005;143:559-569. (Level 1)
28. Hollander P, Ratner R, Fineman M, et al. Addition of pramlintide to insulin therapy lowers HbA1c in conjunction with weight loss in patients with type 2 diabetes approaching glycaemic targets. Diabetes Obes Metab. 2003;5:408-414. (Level 1)
29. Kendall DM, Riddle MC, Rosenstock J, et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care. 2005;28:1083-1091. (Level 1)
30. Nauck MA, Meininger G, Sheng D, Terranella L, Stein PP (Sitagliptin Study 024 Group). Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double blind, non-inferiority trial. Diabetes Obes Metab. 2007;9:194-205. (Level 1)
31. Pramlintide (Symlin) [package insert]. San Diego, CA: Amylin Pharmaceuticals, 2005. (Not rated)
32. Ratner RE, Dickey R, Fineman M, et al. Amylin replacement with pramlintide as an adjunct to insulin therapy improves long-term glycaemic and weight control in type 1 diabetes mellitus: a 1-year, randomized controlled trial. Diabet Med. 2004;21:1204-1212. (Level 1)
33. Rosenstock J, Baron MA, Dejager S, Mills D, Schweizer A. Comparison of vildagliptin and rosiglitazone monotherapy in patients with type 2 diabetes: a 24-week, doubleblind, randomized trial. Diabetes Care. 2007;30:217-223. (Level 1)
34. Rosenstock J, Brazg R, Andryuk PJ, Lu K, Stein P (Sitagliptin Study 019 Group). Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebocontrolled, parallel-group study. Clin Ther. 2006;28:1556-1568. (Level 1)
35. Sitagliptin phosphate (Januvia) [package insert]. West Point, PA: Merck & Co, Inc, 2006. (Not rated)
36. Thompson RG, Gottlieb A, Organ K, Koda J, Kisicki J, Kolterman OG. Pramlintide: a human amylin analogue reduced postprandial plasma glucose, insulin, and C-peptide concentrations in patients with type 2 diabetes. Diabet Med. 1997;14:547-555. (Level 1)
37. Whitehouse F, Kruger DF, Fineman M, et al. A randomized study and open-label extension evaluating the long-term efficacy of pramlintide as an adjunct to insulin therapy in type 1 diabetes. Diabetes Care. 2002;25:724-730. (Level 1)
38. Anderson JH Jr, Brunelle RL, Keohane P, et al (Multicenter Insulin Lispro Study Group). Mealtime treatment with insulin analog improves postprandial hyperglycemia and hypoglycemia in patients with non-insulindependent diabetes mellitus. Arch Intern Med. 1997;157:1249-1255. (Level 1)
39. DeWitt DE, Hirsch IB. Outpatient insulin therapy in type 1 and type 2 diabetes mellitus: scientific review. JAMA. 2003;289:2254-2264. (Level 4)
40. Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329:977-986. (Level 1)
41. Hirsch IB, Bergenstal RM, Parkin CG, Wright E Jr, Buse JB. A real-world approach to insulin therapy in primary care practice. Clin Diabetes. 2005;23:78-86. (Level 4)
42. Insulin detemir (Levemir) [package insert]. Princeton, NJ: Novo Nordisk, 2005. (Not rated)
43. Insulin human (rDNA origin) inhalation powder (Exubera) [package insert]. New York, NY: Pfizer Inc, 2006. (Not rated)
44. 50% NPL/50% lispro (lispro mix 50/50) [package insert]. Indianapolis, IN: Eli Lilly and Company, 2006. (Not rated)
45. Ohkubo Y, Kishikawa H, Araki E, et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract. 1995;28:103-117. (Level 1)
46. Raskin P, Allen E, Hollander P, et al (INITIATE Study Group). Initiating insulin therapy in type 2 diabetes: a comparison of biphasic and basal insulin analogs. Diabetes Care. 2005;28:260-265. (Level 1)
47. Raskin P, Bode BW, Marks JB, et al. Continuous subcutaneous insulin infusion and multiple daily injection therapy are equally effective in type 2 diabetes: a randomized, parallel-group, 24-week study. Diabetes Care. 2003;26: 2598-2603. (Level 2)
48. Riddle MC, Rosenstock J, Gerich J (Insulin Glargine 4002 Study Investigators). The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care. 2003;26:3080-3086. (Level 1)
49. Rosenfalck AM, Thorsby P, Kjems L, et al. Improved postprandial glycaemic control with insulin aspart in type 2 diabetic patients treated with insulin. Acta Diabetol. 2000;37:41-46. (Level 2)
50. Royle P, Waugh N, McAuley L, McIntyre L, Thomas S. Inhaled insulin in diabetes mellitus. Cochrane Database Syst Rev. 2004;CD003890. (Level 1)
51. Schiffrin A, Belmonte M. Multiple daily self-glucose monitoring: its essential role in long-term glucose control in insulin-dependent diabetic patients treated with pump and multiple subcutaneous injections. Diabetes Care. 1982;5:479-484. (Level 2)
52. Writing Team for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Effect of intensive therapy on the microvascular complications of type 1 diabetes mellitus. JAMA. 2002;287:2563-2569. (Level 1)
53. Glimepiride (Amaryl) [package insert]. Bridgewater, NJ: Sanofi-Aventis U.S., 2005. (Not rated)
54. Glipizide (Glucotrol) [package insert]. New York, NY: Pfizer Inc, 2000. (Not rated)
55. Glyburide (DiaBeta) [package insert]. Bridgewater, NJ: Sanofi-Aventis U.S., 2004. (Not rated)
56. Glyburide (Micronase) [package insert]. New York, NY: Pfizer Inc, 2002. (Not rated)
57. Hanefeld M, Bouter KP, Dickinson S, Guitard C. Rapid and short-acting mealtime insulin secretion with nateglinide controls both prandial and mean glycemia. Diabetes Care. 2000;23:202-207. (Level 1)
58. Horton ES, Clinkingbeard C, Gatlin M, Foley J, Mallows S, Shen S. Nateglinide alone and in combination with metformin improves glycemic control by reducing mealtime glucose levels in type 2 diabetes. Diabetes Care. 2000;23:1660-1665. (Level 1)
59. Jovanovic L, Dailey G III, Huang WC, Strange P, Goldstein BJ. Repaglinide in type 2 diabetes: a 24-week, fixed-dose efficacy and safety study. J Clin Pharmacol. 2000;40:49-57. (Level 1)
60. Nateglinide (Starlix) [package insert]. East Hanover, NJ: Novartis Corporation, 2004. (Not rated)
61. Nattrass M, Lauritzen T. Review of prandial glucose regulation with repaglinide: a solution to the problem of hypoglycaemia in the treatment of type 2 diabetes? Int J Obes Relat Metab Disord. 2000;24(Suppl 3):S21-S31. (Level 4)
62. Repaglinide (Prandin) [package insert]. Princeton, NJ: Novo Nordisk, 2004. (Not rated)
63. Schade DS, Jovanovic L, Schneider J. A placebo-controlled, randomized study of glimepiride in patients with type 2 diabetes mellitus for whom diet therapy is unsuccessful. J Clin Pharmacol. 1998;38:636-641. (Level 1)
64. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) [erratum in Lancet. 1999;354:602]. Lancet. 1998;352:837-853. (Level 1)
65. Wolffenbuttel BH, Nijst L, Sels JP, Menheere PP, Muller PG, Kruseman AC. Effects of a new oral hypoglycaemic agent, repaglinide, on metabolic control in sulphonylurea-treated patients with NIDDM. Eur J Clin Pharmacol. 1993;45:113-116. (Level 2)
66. Zimmerman BR. Sulfonylureas. Endocrinol Metab Clin North Am. 1997;26:511-522. (Level 4)
67. Bailey CJ, Turner RC. Metformin. N Engl J Med. 1996;334:574-579. (Level 4)
68. DeFronzo RA, Goodman AM (Multicenter Metformin Study Group). Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. N Engl J Med. 1995;333:541-549. (Level 1)
69. Garber AJ, Duncan TG, Goodman AM, Mills DJ, Rohlf JL. Efficacy of metformin in type II diabetes: results of a double-blind, placebo-controlled, doseresponse trial. Am J Med. 1997;103:491-497. (Level 1)
70. Grant PJ. The effects of high- and medium-dose metformin therapy on cardiovascular risk factors in patients with type II diabetes. Diabetes Care. 1996;19:64-66. (Level 2)
71. Hundal RS, Krssak M, Dufour S, et al. Mechanism by which metformin reduces glucose production in type 2 diabetes. Diabetes. 2000;49:2063-2069. (Level 2)
72. Johansen K. Efficacy of metformin in the treatment of NIDDM: meta-analysis. Diabetes Care. 1999;22:33-37. (Level 1)
73. Metformin (Glucophage) [package insert]. Princeton, NJ: Bristol-Myers Squibb Company, 2003. (Not rated)
74. Metformin (Glucophage XR) [package insert]. Princeton, NJ: Bristol-Myers Squibb Company, 2004. (Not rated)
75. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34) [erratum in Lancet. 1998;352:1558]. Lancet. 1998;352:854-865. (Level 1)
76. Cavalot F, Petrelli A, Traversa M, et al. Postprandial blood glucose is a stronger predictor of cardiovascular events than fasting blood glucose in type 2 diabetes mellitus, particularly in women: lessons from the San Luigi Gonzaga Diabetes Study. J Clin Endocrinol Metab. 2006;91:813-819. (Level 2)
77. Esposito K, Giugliano D, Nappo F, Marfella R. Regression of carotid atherosclerosis by control of postprandial hyperglycemia in type 2 diabetes mellitus. Circulation. 2004;110:214-219. (Level 2)
78. Esposito K, Nappo F, Marfella R, et al. Inflammatory cytokine concentrations are acutely increased by hyperglycemia in humans: role of oxidative stress. Circulation. 2002;106:2067-2072. (Level 2)
79. Hanefeld M, Koehler C, Schaper F, Fuecker K, Henkel E, Temelkova-Kurktschiev T. Postprandial plasma glucose is an independent risk factor for increased carotid intima-media thickness in non-diabetic individuals. Atherosclerosis. 1999;144:229-235. (Level 2)
80. Marfella R, Quagliaro L, Nappo F, Ceriello A, Giugliano D. Acute hyperglycemia induces an oxidative stress in healthy subjects. J Clin Invest. 2001;108:635-636. (Level 2)
81. Monnier L, Collette C, Dunseath GJ, Owens DR. The loss of postprandial glycemic control precedes stepwise deterioration of fasting with worsening diabetes. Diabetes Care. 2007;30:263-269. (Level 2)
82. Monnier L, Lapinski H, Colette C. Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA(1c). Diabetes Care. 2003;26:881-885. (Level 2)
83. Karter AJ, Ackerson LM, Darbinian JA, et al. Selfmonitoring of blood glucose levels and glycemic control: the Northern California Kaiser Permanente Diabetes registry. Am J Med. 2001;111:1-9. (Level 3)
84. Saudek CD, Derr RL, Kalyani RR. Assessing glycemia in diabetes using self-monitoring blood glucose and hemoglobin A1c. JAMA. 2006;295:1688-1697. (Level 1)
85. Schwedes U, Siebolds M, Mertes G (SMBG Study Group). Meal-related structured self-monitoring of blood glucose: effect on diabetes control in non-insulin-treated type 2 diabetic patients. Diabetes Care. 2002;25:1928-1932. (Level 1)
86. Welschen LM, Bloemendal E, Nijpels G, et al. Self-monitoring of blood glucose in patients with type 2 diabetes who are not using insulin: a systematic review. Diabetes Care. 2005;28:1510-1517. (Level 1)
87. Aronoff S, Rosenblatt S, Braithwaite S, Egan JW, Mathisen AL, Schneider RL (Pioglitazone 001 Study Group). Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response study. Diabetes Care. 2000;23:1605-1611. (Level 1)
88. Dormandy JA, Charbonnel B, Eckland DJ, et al (PROactive investigators). Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet. 2005;366:1279-1289. (Level 1)
89. Einhorn D, Rendell M, Rosenzweig J, Egan JW, Mathisen AL, Schneider RL (Pioglitazone 027 Study Group). Pioglitazone hydrochloride in combination with metformin in the treatment of type 2 diabetes mellitus: a randomized, placebo-controlled study. Clin Ther. 2000;22: 1395-1409. (Level 2)
90. Gerstein HC, Yusuf S, Bosch J, et al (DREAM [Diabetes REduction Assessment with ramipril and rosiglitazone Medication] Trial Investigators). Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial [erratum in Lancet. 2006;368:1770]. Lancet. 2006;368:1096-1105. (Level 1)
91. Kahn SE, Haffner SM, Heise MA, et al (ADOPT Study Group). Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy [erratum in N Engl J Med. 2007;356:1387-1388]. N Engl J Med. 2006;355:2427-2443. (Level 1)
92. Lebovitz HE, Dole JF, Patwardhan R, Rappaport EB, Freed MI (Rosiglitazone Clinical Trials Study Group). Rosiglitazone monotherapy is effective in patients with type 2 diabetes. J Clin Endocrinol Metab. 2001;86:280-288. (Level 1)
93. Mazzone T, Meyer PM, Feinstein SB, et al. Effect of pioglitazone compared with glimepiride on carotid intimamedia thickness in type 2 diabetes: a randomized trial. JAMA. 2006;296:2572-2581. (Level 2)
94. Mudaliar S, Henry RR. New oral therapies for type 2 diabetes mellitus: the glitazones or insulin sensitizers. Annu Rev Med. 2001;52:239-257. (Level 4)
95. Phillips LS, Grunberger G, Miller E, Patwardhan R, Rappaport EB, Salzman A (Rosiglitazone Clinical Trials Study Group). Once- and twice-daily dosing with rosiglitazone improves glycemic control in patients with type 2 diabetes [erratum in Diabetes Care. 2001;24:973]. Diabetes Care. 2001;24:308-315. (Level 1)
96. Pioglitazone (Actos) [package insert]. Deerfield, IL: Takeda Pharmaceuticals America, Inc, 2004. (Not rated)
97. Pioglitazone + metformin (Actoplus Met) [package insert]. Deerfield, IL: Takeda Pharmaceuticals America, Inc, 2005. (Not rated)
98. Rosiglitazone (Avandia) [package insert]. Research Triangle Park, NC: GlaxoSmithKline, 2005. (Not rated)